protein

GFAP, Human (Glial Fibrillary Acidic Protein)

MBS634970

0.05 mg

575 USD

Protein

GFAP, Human (Glial Fibrillary Acidic Protein)

GFAP

glial fibrillary acidic protein isoform 3; Glial fibrillary acidic protein; glial fibrillary acidic protein; glial fibrillary acidic protein

GFAP; GFAP; GFAP

GFAP_HUMAN

Human, normal brain

>90% (SDS-PAGE). Two stagged tissue extraction hydroxyapatit column; GFAP preparations represented by specific protein bands 43-49 kD. The major two bands appear in the region of the 46kD.

Supplied as a suspension in 800mM urea, 1mM sodium phosphate, 16mM sodium bicarbonate. No preservative added.

May be stored at 4 degree C for short-term only. For long-term storage, aliquot and store at -20 degree C. Aliquots are stable for at least 12 months at -20 degree C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Western Blot (WB)

Suitable for use in Western Blot.

Growth Factors, Cytokines; Growth Factors-GFAP

Protein (GFAP), as a member of the cytoskeletal protein family, is the principal 8-9nm intermediate filament in mature astrocytes of the central nervous system (CNS). GFAP is a monomeric molecule with a molecular mass between 40 and 53kD and an isoelectric point between 5.7 and 5.8. GFAP is a highly brain-specific protein that is not found outside the CNS. Findings have shown that while GFAP is released into the blood very soon after traumatic brain injury (TBI) based on its severity, GFAP is not released after even multiple traumae in the absence of brain injury. In the CNS, following injury, either as a result of trauma, disease, genetic disorders, or chemical insult, astrocytes become reactive and respond in a typical manner, termed astrogliosis. Astrogliosis is characterized by the rapid synthesis of GFAP. GFAP normally increases with age and there is a wide variation in the collection and processing of human brain tissue. Thanks to its high brain specificity and early release from the CNS after TBI, GFAP might be a suitable marker for early diagnostics.

334688844

NP_001229305.1

NM_001242376.1

P14136

~46kD

Neural Crest Differentiation Pathway (672460); Nuclear Signaling By ERBB4 Pathway (530744); Signal Transduction Pathway (477114); Signaling By ERBB4 Pathway (530741); Spinal Cord Injury Pathway (739007)

This gene encodes one of the major intermediate filament proteins of mature astrocytes. It is used as a marker to distinguish astrocytes from other glial cells during development. Mutations in this gene cause Alexander disease, a rare disorder of astrocytes in the central nervous system. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Oct 2008]

GFAP: a class-III intermediate filament protein. A cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells. Mutations in this gene cause Alexander disease, a rare disorder of astrocytes in the central nervous system. An additional transcript variant isoform has been described, but its full length sequence has not been determined. Protein type: Cytoskeletal. Chromosomal Location of Human Ortholog: 17q21. Cellular Component: membrane; cytoplasm; intermediate filament; cytosol. Molecular Function: integrin binding; structural constituent of cytoskeleton; kinase binding. Biological Process: Bergmann glial cell differentiation; extracellular matrix organization and biogenesis; regulation of neurotransmitter uptake; response to wounding; neurite regeneration; intermediate filament organization; astrocyte development. Disease: Alexander Disease

0.05 mg

575 USD